SPOP and cancer: The association between SPOP mutations and better prognosis was also detected in a cohort of 121 patients with de novo mHSPC treated with ADT: both the median PFS and OS were significantly improved in the subset of 25 men with SPOP-mutated cancers (mPFS: 35 vs. 13 months, p = 0.016; mOS: 97 vs. 69 months, p = 0.027) [72].